This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Xenetic Biosciences PLC
Drug Names(s): rhH1.3
Description: Oncohist is a recombinant derivative of human histone H1.3.
Deal Structure: Oncohist was originally developed by SymbioTec.
In March 2008, SymbioTec signed an exclusive license agreement for the drug development of ONCOHIST in the Russian Federation and Ukraine with Cryonix St. Petersburg.
In March 2011, Human Stem Cell Institute acquired a 50% stake in Cryonix, its long-term partner in St Petersburg, for Rb4.6 million ($160,000) and said that it may buy more shares in the future.
In August 2011, Lipoxen announced that it intends to acquire the entire issued share capital of SymbioTec for a total consideration of GBP8.8 million, which is to be satisfied by the issue of 80 million new ordinary shares in the capital of Lipoxen. The transaction closed in January 2012.
In September 2011, Lipoxen plc changed its name to Xenetic Biosciences plc.
Additional information available to subscribers only: